Ibnsina Pharma reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EGP 5,550.26 million compared to EGP 5,628.78 million a year ago. Net income was EGP 30.99 million compared to EGP 137.2 million a year ago. Basic earnings per share from continuing operations was EGP 0.02 compared to EGP 0.08 a year ago.
For the nine months, sales was EGP 15,811.41 million compared to EGP 15,752.3 million a year ago. Net income was EGP 119.6 million compared to EGP 242.19 million a year ago. Basic earnings per share from continuing operations was EGP 0.1 compared to EGP 0.15 a year ago.